Патогенетическая коррекция анемии эритропоэзстимулирующими препаратами у больных лимфопролиферативными заболеваниями (обзор литературы)

В статье представлен обзор литературы по патогенезу анемического синдрома (АС) у больных с опухолевыми заболеваниями лимфатической системы. Показаны преимущества и недостатки эритропоэзстимулирующих препаратов (Э ПСП), используемых для коррекции АС. Проведен анализ результативности лечения анемического синдрома с помощью Э ПСП при различных видах лимфопролиферативных заболеваний (ЛПЗ). Выделены прогностические факторы, позволяющие предсказать положительный ответ ЭПСП у больных ЛПЗ и снижающие стоимость лечения больных.

1. Blackwell K., Gascón P., Sigounas G., Jolliffe L. rHuEPO and improved treatment outcomes: potential modes of action. Oncologist 2004;9(Suppl 5):41–7.

2. De Gaona E.R., Rifón J., Pérez-Calvo J. et al. Anemia in chronic lymphatic leukemi a: is erythropoietin the solution. Rev Med Univ Navarra 2007;51(1):3–10.

3. Zinzani P.L., Tani M., Alinari L. et al. Role of anemia in survival of patients with elderly aggressive non-Hodgkin’s lymphoma after chemotherapy. Leuk Lymphoma 2005;46(10):1449–54.

4. Samuelsson J. Long-standing resolution of anemia in symptomatic low-grade non- Hodgkin’s lymphoma patients treated with recombinant human erythropoietin as sole therapy. Med Oncol 2002;19(1):69–72.

5. Kyle R.A. Multiple myeloma: review of 869 cases. Mayo Clin Proc 1975;50:29–40.

6. Ludwig H. Anemia of hematologic malignancies: what are the treatment options? Semin Oncol 2002;29 (3 Suppl 8):45–54. 7. Moullet I., Salles G., Ketterer N. et al. Frequency and significance of anemia in non-Hodgkin’s lymphoma patients. Ann Oncol 1998;9:1109–15.

7. Straus D.J. Epoetin alfa therapy for parameters with hematologic malignancies and mild anemia. Clin Lymphoma 2003;4(Suppl 1):13–7.

8. Dammacco F., Luccarelli G., Prete M., Silvestris F. The role of recombinant human erythropoietin alpha in the treatment of chronic anemia in multiple myeloma. Rev Clin Exp Hematol 2002;Suppl 1:32–8.

9. Truong P.T., Parhar T., Hart J. et al. Population-based analysis of the frequency of anemia and its management before and during chemotherapy in patients with malignant lymphoma. Am J Clin Oncol 2010;33(5):465–8.

10. Steurer M., Wagner H., Gastel G. Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey. Wien Klin Wochenschr 2004;116(11–12):367–72.

11. Hershman D.L., Buono D.L. et al. Patterns of Use and Risks Associated With Erythropoiesis-Stimulating Agents Among Medicare Patients With Cancer. J Natl Cancer Inst 2009;101(23):1633–41.

12. Богданов А.Н., Новик А.А. Диагностика и дифференциальная диагностика анемий. Вестн Гематологии 2005;1(4):63–70.

13. Mittelman M. The implications of anemia in multiple myeloma. Clin Lymphoma 2003;4(Suppl 1):23–9.

14. Hudis C.A., van Belle S., Chang J., Muenstedt K. rHuEPO and treatment outcomes: the clinical experience. Oncologist 2004;9(Suppl 5):55–69.

15. Eve H.E., Rule S.A. Autoimmune haemolytic anaemia associated with mantle cell lymphoma. Int J Hematol 2010;91(2):322–5.

16. Zent C.S., Ding W., Reinalda M.S. et al. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentationand prognosis. Leuk Lymphoma 2009;50(8):1261–8.

17. Gaya A., Urbano-Ispizua A., Fernández-Avilés F. et al. Anemia associated with impaired rythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment. Biol Blood Marrow Transplant 2008; 14(8):880–7.

18. Mauro F.R., Gentile M., Foa R. Erythropoietin and chronic lymphocytic leukemia. Rev Clin Exp Hematol 2002;Suppl 1:21–31.

19. Гусева С.А. Анемии при хронических и опухолевых заболеваниях. Укр журн гематологии и трансфузиологии 2003;4:32–8.

20. Мулле И., Саль Г., Кеттерер Н. и др. Частота и значение анемии у больных с неходжкинскими лимфомами. Анемия у онкол больных 2002;1:19–21.

21. Littlewood T., Mandelli F. The effects of anemia in hematologic malignancies: more than a symptom. Semin Oncol 2002;29(3)Suppl 8:40–4.

22. Pierce C.N., Larson D.F. Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device. Perfusion 2005;20(2):83–90.

23. Rizzo J.D., Lichtin A.E., Woolf S.H. et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002;100(7):2303–20.

24. Птушкин В.В. Дискуссионные вопросы применения эритропоэтинов в лечении анемии у пациентов с опухолевыми заболеваниями. Онкогематология 2007;2:31–6.

25. Lombard M., Chua E., O’Toole P. Regulation of intestinal non-haem iron absorbtion. Gut 1997;40:435–9.

26. Johnson R.A., Waddelow T.A., Caro J. et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989; 74:130–8.

27. Moldawer L.L., Marano M.A., Wei H. et al. Cachectin/tumor necrosis factoralpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989; 3:1637–43.

28. Сараева Н.О. Механизмы развития анемии при гемобластозах. Гематол и трансфузиол 2007;52(1):31–7.

29. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47–95.

30. Tsopra O.A., Ziros P.G., Lagadinou E.D. et al. Disease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a possible pathogenetic role for tumor necrosis factoralpha. Acta Haematol 2009;121(4):187–95.

31. Гуревич К.Я., Константинов Ю.В., Коробицын Л.П. и др. Человеческий рекомбинантный эритропоэтин (эпокрин) в лечении анемии. Практическое руководство. СПб., 2004. 60 с.

32. Павлов А.Д., Морщакова Е.Ф., Демихов В.Г. и др. Применение рекормона (человеческого рекомбинантного эритропоэтина бета) в лечении эритропоэтиндефицитных анемий у детей и подростков. Пособие для врачей-гематологов и педиатров. Рязань, 2004. 48 с.

33. Романенко Н.А. Коррекция и лечение анемии у больных с гемобластозами эритроцитсодержащими компонентами крови и препаратами рекомбинантного эритропоэтина. Вестн Гематологии 2007;3(4):46–54.

34. Singh A., Eckardt K.U., Limmermann A. et al. Increased plasma viscosity as a reason for inappropriate erythropoietin formation. J Clin Invest 1993;91:251–6.

35. Takagi M., Migamoto Y., Kosaka M. et al. Clinical significance of serum erythropoietin levels in patients with multiple myeloma. Rinsho Ketsueki 1992;33:1151–7.

36. Han B., Shi Y.K., Zhu J. et al. Study on serum erythropoietin levels in patients with hematologic malignancies. Zhonghua Xue Ye Xue Za Zhi 2006;27(8):543–5.

37. Osterborg A., Boogaerts M.A., Cimino R. et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma — a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma. Blood 1996;87(7):2675–82.

38. Поспелова Т.И., Лямкина А.С. Уровень цитокинов (интерлейкина-1β, фактора некроза опухолей-α, интерферона-γ, интерлейкина-6) у больных лимфопролиферативными заболеваниями с анемическим синдромом. Анемия при лимфомах: научное издание. НГМУ, Новосибирск, 2008. С. 97–114.

39. Ludwig H., Fritz E. Anemia in Cancer patients. Semin Oncol 1998; 25(3)Suppl 7:2–6.

40. Абдулкадыров К.М. Переливания эритроцитов. В кн. Клиническая гематология: Справочник. СПб.: Питер, 2006. С. 403–406.

41. Приказ Минздрава РФ № 363 от 25 ноября 2002 года «Об утверждении Инструкции по применению компо нентов крови».

42. Шевченко Ю.Л., Заривчацкий М.Ф., Жибурт Е.Б. Трансфузионные осложнения и их рофилактика. В кн.: Шев ченко Ю.Л., Шабалин В.Н., Заривчацкий М.Ф., Селиванов Е.А. (ред.) Руководство по общей и клинической трансфузиологии. СПб.: ООО «Издательство Фолиант», 2003. С. 561–588.

43. Ильина Е.Н., Говорун В.М. и Иваников И.О. Некоторые аспекты лабора торной диагностики вирусных гепатитов В и С. Тер арх 2003;75(4): 84–6.

44. Елов А.А., Федоров Н.А. и Жибурт Е.Б. Универсальные технологии генотестирования донорской крови и других клинических материалов на патогены. Трансфузиология 2006;7(3):98–118.

45. Ярославцева Н.Г., Грумбкова Л.О., Туполева Т.А. и др. Вирусная безопасность гемотрансфузий: обеспечивают ли ее принятые лабораторные методы выбраковки донорской крови по гепатитам В и С. Г ематол и трансфузиол 2006;51(2):22–6.

46. Жибурт Е.Б., Караваев А.В., Филина Н.Г., Губанова М.Н. Модернизация бактериальной безопасности в трансфузиологии. Трансфузиология 2011;11(4):38–48.

47. Theakston E.P., Morris A.J., Streat S.J. et al. Transfusion transmitted Yersinia enterocolitica infection in New Zealand. Ausr N Z Med 1997;27(1):62–7.

48. Brecher M.E., Hay S.N. Bacterial contamination of blood components. Clin Microbiol Rev 2005;18(1):195–204.

49. Kuehnert M.J., Roth V.R., Haley N.R. et al. Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001;41(12):1493–9.

50. Hershman D.L., Buono D.L., Malin J. et al. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 2009;101(23):1633–41.

51. Henke M., Laszig R., Rube C. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–60.

52. Wright J.R., Ung Y.C., Julian J.A. et al. Randomized, double-blind, placebocontrolled trial of erythropoietin in nonsmall-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25(9):1027–32.

53. Henry D.H. Guidelines and recommendations for the management of anemia in patients with lymphoid malignancies. Drugs 2007;67(2):175–94.

54. Bennett C.L., Silver S.M., Djulbegovic B. et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299(8):914–24.

55. Bohlius J., Wilson J., Seidenfeld J. et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98(10):708–14.

56. Bohlius J., Schmidlin K., Brillant C. et al. Recombinant human erythropoiesisstimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009;373:1532–42.

57. Yan J., Wang S., Mi J.B. et al. Production and characterization of anti-recombinant human erythropoietin (rhEPO) monoclonal antibody. J Immunoassay Immunochem 2004;25(1):91–101.

58. Лапчинская И.Н. Красноклеточная аплазия как осложнение терапии эритропоэтином: современное состояние проблемы. Укр журн гематологии и трансфузиологии 2004;3(4):45–7.

59. Casadevall N., Nataf J., Viron B. Pure red-cell aplasia and antierythropoietin antibodies in patients with recombinant erythropoietin. N Engl J Med 2002; 246:469–75.

60. Захаров Ю.М. Цитопротективные функции эритропоэтина. Клин нефрол 2009;1:16–21.

61. Kumar S.M., Yu H., Fong D. et al. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Melanoma Res 2006;16(4):275–83.

62. Ribatti D. Erythropoietin and tumor angiogenesis. Stem Cells Dev 2010;19(1):1–4.

63. Brines M.L., Ghezzi P., Keenan S. et al. Erythropoietin crosses the bloodbrain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 2000;97:10526–31.

64. Westenbrink B.D., Lipsic E., van der Meer P. et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor-mediated neovascularization. Eur Heart J 2007;28:2018–27.

65. Urao N., Okigaki M., Yamada H. rythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res 2006;98:1405–13.

66. Sartelet H., Fabre M., Castaing M. et al. Expression of erythropoietin and its receptor in neuroblastomas. Cancer 2007;110(5):1096–106.

67. Kumar S.M., Acs G., Fang D. et al. Functional erythropoietin autocrine loop in melanoma. Am J Pathol 2005;166(3):823–30.

68. Acs G., Zhang P.J., McGrath C.M. et al. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003;162(6):1789–806.

69. Романенко Н.А., Бессмельцев С.С., Розанова О.Е. и др. Влияние уровня ФНО-альфа на эффективность коррекции анемии у больных лимфопролиферативными заболеваниями. Онкогематология 2010;3:22–8.

70. Steinbrook R. Medicare and erythropoietin. N Engl J Med; 356(1):4–6.

71. Straus D.J. Epoetin alfa therapy for parameters with hematologic malignancies and mild anemia. Clin Lymphoma 2003;4(Suppl 1):13–7.

72. Ludwig H., Rai K., Blade J. et a l. Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J 2002;3(3):121–30.

73. Ludwig H., Fritz E., Kotzmann H. et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693–9.

74. Musto P., Falcone A., D’Arena G. et al. Clinical results of recombinant human erythropoietin in transfusion-dependent patients with refractory multiple myeloma; role of cytokines and monitoring of erythropoiesis. Eur J Haematol 1997;58:314–9.

75. Dammacco F., Silvestris F., Castoldi G.L. et al. The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. Int J Clin Lab Res 1998;28(2):127–34.

76. Dammacco F., Castoldi G., Rodjer S. Efficacy of epoetin alfa in treatmentof anemia of multiple myeloma. Br J Haematol 2001;113(1):172–9.

77. Katodritou E., Terpos E., Zervas K. et al. Hypochromic erythrocytes ( %): a reliable marker for recognizing ironrestricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma. Ann Hematol 2007;86(5):369–76.

78. Glossmann J.P., Engert A., Wassmer G. et al. Recombinant human erythropoietin, epoetin beta, in patients with relapsed ymphoma treated with aggressive sequential salvage chemotherapy — results of a randomized trial. Ann Hematol 2003;82(8):469–75.

79. Siakantaris M.P., Angelopoulou M.K., Vassilakopoulos T.P. et al. Correction of disease related anemia of B-chronic lymphoproliferative disorders by recombinant human erythropoietin: maintenance is necessary to sustain response. Leuk Lymphoma 2000; 40(1–2):141–7.

80. Osterborg A., Brandberg Y., Molostova V. et al. Randomized, doubleblind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 2002;20(10):2486–94.

81. Yang S., Jun M., Hong-Li Z. et al. A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin’s lymphoma, or chronic lymphocytic leukemia in Chinese population. Int J Hematol 2008;88(2):139–44.

82. Straus D.J., Testa M.A., Sarokhan B.J. et al. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer 2006;107(8):1909–17.

83. Cazzola M., Beguin Y., Kloczko J. et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin Production. Br J Haematol 2003;122(3):386–93.

84. Osterborg A., Steegmann J.L., Hellmann A. Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin’s lymphoma receiving combination chemotherapy. Br J Haematol 2007;136(5):736–44.

85. Schmitt S., Mailaender V., Egerer G. et al. Successful autologous peripheral blood stem cell transplantation in a Jehovah’s Witness with multiple myeloma: review of literature and recommendations for high-dose chemotherapy without support of allogeneic blood products.

86. Int J Hematol 2008;87(3):289–97.

87. Baron F., Frère P., Fillet G., Beguin Y. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.

88. Clin Cancer Res 2003;9(15):5566–72.

89. Martino M., Oliva E., Console G. et al. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. Support Care Cancer 2005;13(3):182–7.

90. Hunault-Berger M., Tanguy-Schmidt A., Rachieru P. et al. rHuEpo before high-dose therapy allows autologous peripheral stemcell transplantation without red blood cell transfusion: a pilot study. Bone Marrow Transplant 2005;35(9):903–7.

91. Olivieri A., Scortechini I., Capelli D . et al. Combined administration of alphaerythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. Bone Marrow Transplant 2004;34(8):693–702.

92. Hart C., Grassinger J., Andreesen R., Hennemann B. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor

93. cells. Bone Marrow Transplant 2009; 43(3):197–206.

94. Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 1998; 25(3 Suppl 7):27–34.

95. Hedenus M., Birgegård G., Näsman P. et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007;21(4):627–32.

96. Katodritou E., Speletas M., Zervas K. et al. Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r -HuEPO in anemic patients with multiple myeloma. Lab Hematol 2006;12(1):47–54.

97. Cazzola M., Messinger D., Battistel V. et al. Recombinant human erythropoietin in anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: Dose finding and identification of predictors of respons. Blood 1995;86:4446–53.

98. Cervantes F., Alvarez-Larrán A., Hernández-Boluda J.C. et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004;127(4):399–403.

99. Henry D.H. Clinical application of recombinant erythropoietin in anemic cancer patients. Hematol Oncol Clin North Am 1994;8(5):961–73.

100. Ludwig H., Leitgeb C., Fritz E. e t al. Erythropoietin treatment of chronic anemia of cancer. Eur J Cancer 1993;29A(Suppl 2):8–12.

101. Гусева С.А., Дарушин Е.В. и Гончаров Я.П. Коррекция анемии рекомбинантным эритропоэтиномальфа у больных миеломной болезнью. Укр журн гематологии и трансфузиологии 2003;5:11–6.